[Intravitreal anti-VEGF therapy for capillary hemangioblastomas in von Hippel-Lindau disease]

Klin Monbl Augenheilkd. 2008 Apr;225(4):292-4. doi: 10.1055/s-2008-1027175.
[Article in German]

Abstract

Background: Up-regulated expression of the vascular endothelial growth factor (VEGF) in von Hippel-Lindau (VHL) disease has been postulated to induce retinal hemangioblastoma. Intravitreal injections of anti-VEGF drugs might provide a new therapeutic option in this condition.

Methods: In a single case decision a patient with active retinal hemangioblastomas due to VHL disease received repeated intravitreal injections of 0.5 mg ranibizumab.

Results: Subsequent to intravitreal anti-VEGF therapy, the signs of activity of the retinal hemangioblastomas slowly regressed.

Conclusions: Intravitreal anti-VEGF therapy might, as monotherapy or as combination therapy, offer a new treatment option for retinal hemangioblastoma.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adult
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Drug Administration Schedule
  • Endothelium, Vascular / drug effects
  • Female
  • Hemangioblastoma / blood supply
  • Hemangioblastoma / drug therapy*
  • Humans
  • Injections
  • Ophthalmoscopes
  • Ranibizumab
  • Retinal Neoplasms / blood supply
  • Retinal Neoplasms / drug therapy*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Visual Acuity / drug effects
  • Vitreous Body
  • von Hippel-Lindau Disease / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Ranibizumab